Rituximab, cladribine and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG ‐ CLL4 (ML21283) trial
ConclusionsThe study confirmed the high efficacy and acceptable safety profile of induction therapy with RCC and maintenance therapy with rituximab in previously untreated patients with CLL.This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - Category: Hematology Authors: Tadeusz Robak, Jerzy Blonski, Aleksander Bart łomiej Skotnicki, Magdalena Piotrowska, Tomasz Wróbel, Justyna Rybka, Janusz Kłoczko, Łukasz Bołkun, Bożena Katarzyna Budziszewska, Urszula Walczak, Anatoly Uss, Marta Fidecka, Piotr Smolewski Tags: Original Article Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia | Rituxan | Study